156 unknown. 156 Phase 2, 63 Phase 1, 9 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 156 | Unknown 156 |
| Phase 1 | 63 | Unknown 63 |
| Phase 3 | 9 | Unknown 9 |
Follow Hemostatic Disorders: new trials by email Literature Review of Hemostatic Disorders trials Research Report on Hemostatic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma Anti-BCMA CAR-NK - Multiple Myeloma, Refractory | Phase 1 / Phase 2 | Unknown | Shahid Beheshti University of Medical Sciences | 10 | 2024-04-30 | 2024-03-06 |
| A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma CM313 injection - Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Keymed Biosciences Co.Ltd | 120 | 2024-02-28 | 2023-11-13 |
| A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma KQ-2003 CAR T-cells - Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Novatim Immune Therapeutics (Zhejiang) Co., Ltd. | 29 | 2024-01-11 | 2024-01-25 |
| Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS Daratumumab, Bortezomib, Lenalidomide - Multiple Myeloma | Phase 2 | Unknown | Stichting European Myeloma Network | 200 | 2023-11-23 | 2024-04-23 |
| CURATE.AI Optimized Modulation for Multiple Myeloma Bortezomib, Cyclophosphamide, Dexamethasone - Multiple Myeloma | Phase 2 / Phase 3 | Unknown | National University Hospital, Singapore | 20 | 2023-09-10 | 2023-09-06 |
| A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia Zanubrutinib, Bendamustine, Rituximab - Waldenström's Macroglobulinemia | Phase 2 | Unknown | Shanghai Changzheng Hospital | 60 | 2023-08-01 | 2023-09-14 |
| A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells - Multiple Myeloma | Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 10 | 2023-07-27 | 2023-11-13 |
| Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia Pazopanib - Hereditary Hemorrhagic Telangiectasia, Epistaxis | Phase 1 / Phase 2 | Unknown | Cure HHT | 30 | 2023-07-01 | 2022-09-08 |
| Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma Mitoxantrone hydrochloride liposome/Dexamethasone/daratumumab - Relapsed/Refractory Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Second Affiliated Hospital of Soochow University | 20 | 2023-05-20 | 2023-05-15 |
| GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies GIC-102 - Advanced Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Unknown | GI Cell, Inc. | 50 | 2023-04-28 | 2024-07-09 |
| Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM Anti-GPRC5D CAR-T Cells Injection - Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | Phase 1 / Phase 2 | Unknown | XuYan | 18 | 2023-04-10 | 2023-04-20 |
| Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM Zanubrutinib, Bendamustine and Rituximab - Waldenstrom Macroglobulinemia | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 42 | 2023-02-15 | 2024-08-28 |
| Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM Anti-GPRC5D CAR-T cells infusion - Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | Phase 1 / Phase 2 | Unknown | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | 18 | 2023-02-07 | 2023-02-23 |
| Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma STI-6129 - Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Sorrento Therapeutics, Inc. | 72 | 2023-02-01 | 2023-04-12 |
| A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma BCMA CAR-T cells - Multiple Myeloma, New Diagnosis Tumor | Phase 2 | Unknown | Zhejiang University | 40 | 2023-01-30 | 2023-02-21 |
| Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies umbilical cord derived mesenchymal stem cells - Hematologic Neoplasms, Neutropenia | Phase 1 / Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 181 | 2023-01-01 | 2023-01-05 |
| PVd Versus Vd in NDMM Patients With RI pomalidomide, Bortezomib, Dexamethasone - Multiple Myeloma | Phase 2 | Unknown | RenJi Hospital | 79 | 2022-12-08 | 2023-01-31 |
| Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement SPD：Selinexor Oral Tablet, Pomalidomide, Dexamethasone - Multiple Myeloma | Phase 2 | Unknown | Peking University People's Hospital | 21 | 2022-10-12 | 2024-01-31 |
| Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma Selinexor, Bortezomib, Lenalidomide - Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Xia Zhongjun | 42 | 2022-07-25 | 2024-06-17 |
| Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma(rr/MM) anti-BCMA/GPRC5D CAR-T CELL - Multiple Myeloma | Phase 2 | Unknown | Xuzhou Medical University | 30 | 2022-05-01 | 2022-08-22 |
Showing 20 of 156. Sign in to see all of them.
Multiple Myeloma (131) · Neoplasms, Plasma Cell (26) · Lymphoma (18) · Waldenstrom Macroglobulinemia (13) · Leukemia (12) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (12) · Recurrence (12) · Leukemia, Lymphocytic, Chronic, B-Cell (11) · Lymphoma, Non-Hodgkin (11) · Leukemia, Myeloid, Acute (10) · Hodgkin Disease (9) · Lymphoma, B-Cell, Marginal Zone (9) · Lymphoma, Follicular (9) · Lymphoma, Large B-Cell, Diffuse (9) · Myelodysplastic Syndromes (9)
Cardiovascular Diseases (156) · Hemic and Lymphatic Diseases (156) · Hemorrhagic Disorders (156) · Vascular Diseases (156) · Hematologic Diseases (152) · Immune System Diseases (145) · Immunoproliferative Disorders (143) · Lymphoproliferative Disorders (142) · Neoplasms by Histologic Type (140) · Paraproteinemias (140) · Blood Protein Disorders (139) · Neoplasms (138) · Neoplasms, Plasma Cell (116) · Lymphatic Diseases (32)
Dexamethasone (45) · Bortezomib (27) · Cyclophosphamide (19) · Lenalidomide (15) · Melphalan (12) · pomalidomide (12) · Thalidomide (10) · daratumumab (10) · Bendamustine Hydrochloride (6) · carfilzomib (6) · Busulfan (4) · Filgrastim (4) · Rituximab (4) · isatuximab (4) · ixazomib (4)
Hellenic Society of Hematology (5) · Samsung Medical Center (4) · Azienda Ospedaliera San Giovanni Battista (3) · Chinese PLA General Hospital (3) · Chonnam National University Hospital (3) · Herbert Irving Comprehensive Cancer Center (3) · Korean Multiple Myeloma Working Party (3) · National University Hospital, Singapore (3) · Oncotherapeutics (3) · Ascentage Pharma Group Inc. (2) · Assistance Publique - Hôpitaux de Paris (2) · Henrik Gregersen (2) · Kosin University Gospel Hospital (2) · LifeTime Pharmaceuticals (2) · Medical College of Wisconsin (2)
China (43) · United States (28) · South Korea (15) · Italy (9) · Germany (8) · Greece (6) · France (5) · Spain (5) · Canada (4) · Denmark (4) · Poland (4) · Singapore (4) · Israel (3) · Netherlands (3) · Sweden (3)
Evangelos Terpos, Prof (3) · Arnon Nagler, MD (2) · Benedetto Bruno, MD, PhD (2) · David G. Savage, MD (2) · Henrik Gregersen, MD (2) · Suzin Mayerson, PhD (2) · Yifan Zhai, MD, PhD (2) · Aihua Zhang, M.D. (1) · Ajai Chari, MD (1) · Ajay Nooka, MD, MPH (1) · Albrecht Reichle, Professor (1) · Alessandro Gozzetti, Medicine (1) · Andrea Velardi, MD, PhD (1) · Ardeshir Ghavamzadeh, MD (1) · Bellal Joseph, MD (1)
PMID 11231246, PMID 12510709, PMID 15107815, PMID 15131807, PMID 15141377, PMID 15189396, PMID 15711856, PMID 15842354, PMID 16103468, PMID 16427380, PMID 16475046, PMID 17360989, PMID 17859247, PMID 18094721, PMID 18239868, PMID 18276714, PMID 19064724, PMID 19095121, PMID 19166855, PMID 19387663, PMID 19952380, PMID 20006130, PMID 20011381, PMID 20109630, PMID 20637084, PMID 20937093, PMID 21872920, PMID 21911830, PMID 21932016, PMID 22315264, PMID 22409262, PMID 22413048, PMID 22897964, PMID 2295392, PMID 23089912, PMID 23470618, PMID 23775099, PMID 23849147, PMID 23903204, PMID 23919993, PMID 24038922, PMID 24239254, PMID 24523121, PMID 24749117, PMID 25433198, PMID 25603811, PMID 26889922, PMID 26986753, PMID 27053773, PMID 27170327
2019 (2), 2005 (1), 2014 (1), 2015 (1), P30CA138292 (1)